Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.
Cardior Pharmaceuticals has raised $75.3M in total funding. The most recent round was Series B. The last funding was announced in August 2021.
Cardior Pharmaceuticals's investors include HTGF (High-Tech Gruenderfonds), Bristol-Myers Squibb, Inkef, EQT Life Sciences, Sunstone Partners.
Cardior Pharmaceuticals is headquartered in Hanover, Germany.
Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.
Cardior Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cardior Pharmaceuticals — Funding & Investors." VCBacked, August 25, 2021, https://www.vcbacked.co/company/cardior-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2021). Cardior Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cardior-pharmaceuticals
{{cite web |title=Cardior Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/cardior-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated